Jupiter Life Line Q2 FY27 Results: Revenue Rises 16%

Q2 performance highlights

Jupiter Life Line Hospitals Ltd reported consolidated total income of INR 456.5 crore for the quarter ended September 2026, the second quarter of FY27. The company reported EBITDA of INR 106.9 crore and profit after tax of INR 56.4 crore. Revenue was 16% higher than INR 393.6 crore reported in the corresponding quarter of the previous financial year. Net profit was compared with INR 57.4 crore in the year-ago period. The results were discussed during the company’s Q2 and H1 FY27 earnings call held on October 26, 2026.

Earnings call focus on Dombivli

The ramp-up of the Dombivli hospital was a central theme of management’s remarks. Managing Director and CEO Dr Ankit Thakker said the hospital’s EBITDA impact improved to INR 0.2 crore in Q2 from INR 9.5 crore in Q1. Management attributed part of this movement to higher medical admissions during the quarter. It cited a seasonally higher infectious disease burden in the region as a contributor to admissions. The company said Q2 occupancy has historically been higher than Q1 and Q3 at its existing hospitals as well. It added that Dombivli’s overall ramp-up trajectory remained intact.

Half-year financial position

For the first half of FY27, Jupiter Life Line Hospitals reported total income of INR 867.5 crore. EBITDA for the six-month period stood at INR 186.2 crore, while PAT was INR 93.9 crore. The company said Q2 EBITDA rose 34.8% sequentially from Q1 FY27. Its H1 results reflected higher depreciation and finance costs linked to recently commercialised beds and debt-funded capital expenditure. These costs are relevant when assessing why improvement in operating performance may not translate proportionately into profit after tax.

Key operating metrics

The company reported an average revenue per occupied bed, or ARPOB, of INR 71,800. In-patient ARPOB stood at INR 58,700. Average length of stay, or ALOS, was 3.79 days. Occupancy across all hospitals was 59.5% for the first half. Excluding Dombivli, occupancy was higher at 64.8%. This gap indicates that the recently opened Dombivli facility continued to affect consolidated occupancy during its early operating phase.

Financial and operational data

What drove the quarterly income increase

The quarterly income figure of INR 456.5 crore was higher than the INR 393.6 crore reported in Q2 of the prior fiscal year. The available disclosures do not provide a detailed split of revenue by hospital, specialty, or payer mix. However, management linked the Dombivli improvement partly to increased medical admissions in the quarter. Seasonal admission patterns were also identified as a factor, with the company stating that its hospitals have traditionally recorded stronger occupancy in Q2 than in Q1 and Q3. The reported increase in income and sequential EBITDA growth point to stronger operating activity during the period.

Margin and profit considerations

EBITDA of INR 106.9 crore on total income of INR 456.5 crore represented a strong operating result for the quarter. But PAT of INR 56.4 crore was slightly below the INR 57.4 crore cited for the corresponding prior-year quarter. The company’s disclosures referred to higher depreciation and finance costs in H1 FY27 following bed commercialisation and debt-funded capital expenditure. These expenses occur below EBITDA and can affect net profit even when operating performance improves. Investors tracking the company’s results may therefore distinguish between the quarterly operating recovery and costs associated with capacity expansion.

Pune South land acquisition disclosure

The company’s investor presentation filed on October 23, 2026 also disclosed a INR 150 crore land acquisition for Pune South. The provided material does not specify the transaction date, development schedule, capacity, or financing terms beyond the stated land acquisition. It nevertheless forms part of the company’s reported expansion-related activity. Along with recent bed commercialisations, the disclosure provides context for the higher depreciation and finance costs noted in the H1 result commentary. No further operational guidance was included in the supplied earnings-call excerpts.

Market relevance for JLHL investors

For investors in NSE-listed JLHL, the main reported data points are the 16% year-on-year rise in Q2 income, sequential EBITDA improvement, and Dombivli’s reduced EBITDA impact. Occupancy excluding Dombivli was 5.3 percentage points above the all-hospital occupancy figure. This highlights the effect of an early-stage facility on the consolidated operating base. The company did not provide share-price movement, valuation commentary, forecasts, or a revised earnings outlook in the supplied material. As a result, conclusions should remain tied to the reported financial and operating metrics.

Conclusion

Jupiter Life Line Hospitals closed Q2 FY27 with total income of INR 456.5 crore, EBITDA of INR 106.9 crore, and PAT of INR 56.4 crore. Management said Dombivli continued to ramp up, supported in part by seasonally higher medical admissions. The next reported updates on occupancy, Dombivli operations, expansion-related costs, and the Pune South land acquisition will provide further context on the company’s operating progress.